Ovarian cancer

#CureLab Oncology #DNA #endogene.bio #Endometriosis #Genetics #Junevity #MHRA #Ocular diseases #Oncology #Ovarian cancer #Regulatory #UK government #University of California San Francisco #Women's health

This week in Drug Discovery (12 – 16 January) 

News round-up for 12 – 16 January by Bruno Quinney, Content Team at DDW.  This week in DDW, new research in women’s health has uncovered significant findings related to endometriosis and ovarian cancer. Elsewhere, can ageing be reversed?  The top stories:    Discovery reveals endometriosis is not… Read More

#News

Ovarian cancer cells
#CureLab Oncology #DNA #Oncology #Ovarian cancer

Therapy could increase ovarian cancer survival, paper finds 

A novel DNA-based therapy could increase survival rates for women with platinum-resistant ovarian cancer, a new paper reveals.  A new clinical study, published in the International Journal of Gynecological Cancer, shows the DNA-based therapy Elenagen, when administered in combination with standard chemotherapy drug gemcitabine, significantly extended overall survival… Read More

#Cancer Research #News

Natural killer cells
#CAR-T #Natural killer cells #Oncology #Ovarian cancer #UCLA

Scientists develop CAR-NKT cell therapy for ovarian cancer

A new type of immunotherapy called CAR-NKT cell therapy has been shown to be more effective at fighting ovarian cancer than conventional CAR-T cell therapy.   Unlike current cellular immunotherapies that require patient-specific manufacturing and can cost hundreds of thousands of dollars, CAR-NKT cells can be produced… Read More

#Cancer Research #Editor's Choice #News

#AbbVie #Antibody drug conjugate (ADC) #MHRA #Oncology #Ovarian cancer

Elahere gets UK approval in platinum-resistant ovarian cancer

Elahere (mirvetuximab soravtansine) has become the first folate receptor-alpha (FRα) targeted antibody-drug conjugate (ADC) licensed in the UK for the treatment of adults with platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.  It is approved in patients who have received one to three prior systemic treatment… Read More

#News #Regulatory

#Financing #Immunotherapy #Oncology #Ovarian cancer #Scandinavia

TILT Biotherapeutics closes $25 million Series B financing

Finnish biotechnology company TILT Biotherapeutics (Tiltbio) has raised $25.6 million (€22.6 million) in a Series B financing.  The financing will support a Phase II clinical trial of Tiltbio’s lead product, TILT-123, in patients with platinum-resistant epithelial ovarian cancer, a Phase Ib trial in melanoma in combination with TILs and other… Read More

#Business & Investment #News

Gold compound
#Drug resistance #Oncology #Ovarian cancer #RMIT University #Solid tumours

Gold-based drug slows tumour growth by 82%

Gold-based drugs can slow tumour growth in animals by 82% and target cancers more selectively than standard chemotherapy drugs, according to new research.  The study published in the European Journal of Medicinal Chemistry reveals a new gold-based compound that’s 27 times… Read More

#Cancer Research #Editor's Choice #News

Ovarian cancer cells
#Genetics / genomics #Icahn School of Medicine #Immunotherapy #Oncology #Ovarian cancer

Study paves way for improved immunotherapy for ovarian cancer

Researchers have discovered that an eczema-linked protein helps ovarian cancer manipulate its environment to resist immunotherapy, suggesting the potential for a skin drug-based treatment. Scientists at the Icahn School of Medicine at Mount Sinai used spatial genomics technology and preclinical animal models, with tumour specimens from… Read More

#Cancer Research #Editor's Choice #News

Peptide
#Cybrexa Therapeutics #Oncology #Ovarian cancer #Peptide-drug conjugate #Peptides #Phase II trial

Peptide-drug conjugate demonstrates antitumour activity

Cybrexa Therapeutics has dosed the first patient in a Phase II trial of its peptide-drug conjugate (PDC) CBX-12 in ovarian cancer. The primary target patient population for the study is women with platinum-resistant or refractory ovarian cancer who are naïve to TOP1-targeted agents. Read More

#News